For the year ending 2025-12-31, EXOZ had -$6,679,967 decrease in cash & cash equivalents over the period. -$6,671,957 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -9,158,734 |
| Amortization of deferred grant reimbursement | -52,913 |
| Depreciation of property and equipment | 287,961 |
| Non-cash lease expense | 53,367 |
| Stock-based compensation | 1,988,105 |
| Grants receivable | -219,923 |
| Prepaid expenses and other current assets | 19,096 |
| Tax receivable | 105,205 |
| Accounts payable and accrued expenses | 311,085 |
| Due to related party | -26,533 |
| Net cash (used in) operating activities | -6,502,040 |
| Deferred grant reimbursement | 19,699 |
| Purchases of property and equipment | 169,917 |
| Net cash (used in) investing activities | -150,218 |
| Payments on finance lease obligations | 27,709 |
| Net cash provided by (used in) financing activities | -27,709 |
| Net increase (decrease) in cash, cash equivalents | -6,679,967 |
| Cash and cash equivalents - beginning of year | 9,719,310 |
| Cash and cash equivalents - end of year | 3,039,343 |
EXOZYMES INC. (EXOZ)
EXOZYMES INC. (EXOZ)